Quarterly ResultAug 5, 2026, 07:52 AM
Aurora Cannabis Q1 Net Revenue $67.6M; International Medical Up 17%
AI Summary
Aurora Cannabis reported fiscal Q1 2027 net revenue of $67.6 million, a 9% decrease year-over-year, primarily due to lower Canadian medical and consumer cannabis sales. This was partially offset by a 17% increase in international medical cannabis net revenue to $43.3 million. The company posted a net loss from continuing operations of $4.0 million, an improvement from the prior year's $10.2 million loss, but Adjusted EBITDA decreased to $3.4 million. Aurora also highlighted the EU-GMP certification for its acquired Safari Flower Company, strengthening its international supply capabilities, and reiterated its focus on global medical cannabis markets.
Key Highlights
- Net revenue was $67.6 million, a 9% decrease year-over-year.
- International medical cannabis net revenue increased 17% to $43.3 million.
- Canadian medical cannabis net revenue decreased 25% to $20.7 million.
- Net loss from continuing operations improved to $4.0 million from $10.2 million.
- Adjusted EBITDA was $3.4 million, down from $10.8 million year-over-year.
- Maintains $149.1 million in cash, cash equivalents, and short-term investments with no debt.
- Safari Flower Company received three-year EU-GMP certification, enhancing international supply.
- Expects sequential improvement in revenue and Adjusted EBITDA in Q2 FY27.
Price Impact
More from ACB